Risk factors for a differentiation syndrome in patients with acute promyelocytic leukemia
Open Access
- 12 September 2023
- journal article
- Published by Publishing House ABV Press in Oncohematology
- Vol. 18 (3) , 50-56
Abstract
Differentiation syndrome (DS) is a severe complication of acute promyelocytic leukemia and its treatment, which is one of the causes of high early mortality. the similarity of clinical manifestations of DS and other complications that may develop during acute promyelocytic leukemia therapy makes it difficult to diagnose ds. at the same time, untimely initiation of DS therapy with glucocorticosteroids can lead to the patient’s death. The only generally accepted risk factor for ds is initial leukocytosis. Specific markers confirming ds have not yet been found. A number of studies show that in patients with diagnosed DS, the expression of CD56, CD54, CD2, CD15, CD13, markers of immature granulocytes, β2-integrins was more often found on blast cells. exposure to tretinoin increased the expression of chemokine receptors, chemokines, and cytokines by blast cells and vascular endothelium. The influence exerted by atypical promyelocytes, due to their biological characteristics, on the coagulation system suggests an association between hemostasis state and ds development. However, the value of the above markers as predictors or signs of DS still needs to be tested, especially when it comes to non-chemotherapeutic treatment of acute promyelocytic leukemia with arsenic trioxide.Keywords
This publication has 55 references indexed in Scilit:
- Differentiation syndrome in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline chemotherapy: characteristics, outcome, and prognostic factorsBlood, 2009
- Clinical and biological features of acute promyelocytic leukemia patients developing retinoic acid syndrome during induction treatment with all-trans retinoic acid and idarubicinHaematologica, 2008
- Causes and prognostic factors of remission induction failure in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and idarubicinBlood, 2008
- Monocyte chemotactic protein-1 in the migration of differentiated leukaemic cells toward alveolar epithelial cellsEuropean Respiratory Journal, 2008
- Adhesion molecules and differentiation syndrome: phenotypic and functional analysis of the effect of ATRA, As2O3, phenylbutyrate, and G-CSF in acute promyelocytic leukemiaHaematologica, 2007
- Haemostatic problems in acute promyelocytic leukaemiaBlood Reviews, 2006
- Occurrence of thrombotic events in acute promyelocytic leukemia correlates with consistent immunophenotypic and molecular featuresLeukemia, 2006
- Relationship between FLT3 mutation status, biologic characteristics, and response to targeted therapy in acute promyelocytic leukemiaBlood, 2005
- Retinoic acid syndrome in NOD/scid mice induced by injecting an acute promyelocytic leukemia cell lineLeukemia, 2004
- All-Trans Retinoic Acid (ATRA) and the Regulation of Adhesion Molecules in Acute Myeloid LeukemiaLeukemia & Lymphoma, 1996